Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer.

Alex Martinez-MartiEnriqueta FelipFrancesco Mattia MancusoGinevra CaratúJudit MatitoPaolo NuciforoIrene SansanoNely Diaz-MejiaSusana CedrésAna CallejoPatricia IranzoNuria PardoJosep Maria MiquelAlejandro NavarroAna VivancosMiriam Sansó

Published in: British journal of cancer (2021)

At a given point and under selective TKI pressure, a single metastasis biopsy in disseminated tumours from EGFR-mutated NSCLC patients could provide a reasonable assessment of actionable alterations useful for therapeutic decisions.

Keyphrases

tyrosine kinase
epidermal growth factor receptor
small cell lung cancer
advanced non small cell lung cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
ultrasound guided
patient reported
wild type